Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines

被引:342
作者
Badesch, DB
Abman, SH
Ahearn, GS
Barst, RJ
McCrory, DC
Simonneau, G
McLaughlin, VV
机构
[1] Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA
[2] Childrens Hosp, Denver, CO 80218 USA
[3] Columbia Presbyterian Med Ctr, Babies Hosp, Pediat Cardiol Ctr, New York, NY 10032 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Hop Antoine Beclere, Clamart, France
[6] Univ Michigan, Ann Arbor, MI 48109 USA
关键词
anticoagulation; arginine; beraprost; bosentan; calciuin-channel blockers; endothelin; endothelin receptor antagonist; epoprostenol; idiopathic pulmonary arterial hypertension; iloprost; medical therapy; oxygen; primary pulmonary hypertension; prostacyclin; pulmonary arterial hypertension; pulmonary hypertension; secondary pulmonary hypertension; sildenafil; therapy; treatment; treprostinil; vasoreactivity; warfarin;
D O I
10.1378/chest.126.1_suppl.35S
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
Pulmonary arterial hypertension (PAH) is often difficult to diagnose and challenging to treat. Untreated, it is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. The past decade has seen remarkable improvements in therapy, driven largely by the conduct of randomized controlled trials. Still, the selection of most appropriate therapy is complex, and requires familiarity with the disease process, evidence from treatment trials, complicated drug delivery systems, dosing regimens, side effects, and complications. This chapter will provide evidence-based treatment recommendations for physicians involved in the care of these complex patients. Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center.
引用
收藏
页码:35S / 62S
页数:28
相关论文
共 193 条
[1]
Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].
Abenhaim, L ;
Moride, Y ;
Brenot, F ;
Rich, S ;
Benichou, J ;
Kurz, X ;
Higenbottam, T ;
Oakley, C ;
Wouters, E ;
Aubier, M ;
Simonneau, G ;
Begaud, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616
[2]
ROLE OF ENDOTHELIUM-DERIVED RELAXING FACTOR DURING TRANSITION OF PULMONARY CIRCULATION AT BIRTH [J].
ABMAN, SH ;
CHATFIELD, BA ;
HALL, SL ;
MCMURTRY, IF .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 259 (06) :H1921-H1927
[3]
Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome [J].
Adrie, C ;
Holzmann, A ;
Hirani, WM ;
Zapol, WM ;
Hurford, WE .
ANESTHESIOLOGY, 2000, 93 (02) :422-430
[4]
Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension [J].
Aguilar, RV ;
Farber, HW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (05) :1846-1850
[5]
AHN HS, 1991, ADV EXP MED BIOL, V308, P191
[6]
[Anonymous], CARDIAC PROBLEMS PRE
[7]
INTERACTIONS BETWEEN L-ARGININE AND L-GLUTAMINE CHANGE ENDOTHELIAL NO PRODUCTION - AN EFFECT INDEPENDENT OF NO SYNTHASE SUBSTRATE AVAILABILITY [J].
ARNAL, JF ;
MUNZEL, T ;
VENEMA, RC ;
JAMES, NL ;
BAI, CL ;
MITCH, WE ;
HARRISON, DG .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (06) :2565-2572
[8]
Sildenafil ameliorates effects of inhaled nitric oxide withdrawal [J].
Atz, AM ;
Wessel, DL .
ANESTHESIOLOGY, 1999, 91 (01) :307-310
[9]
Badalian SS, 2000, J REPROD MED, V45, P149
[10]
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+